📌 Archived version v1.1 (2026-05-31) — a fixed snapshot for citation. View current version →

SQ-LIP-000016 · v1.1 (archived) · View current version →

Is gestrinone an effective treatment for lipedema?

TreatmentPharmacology
Also asked as
Current answer

Based on currently indexed evidence, there is no evidence either way that gestrinone is an effective treatment for lipedema. A high-quality PRISMA systematic review (2025, low risk of bias) identified zero clinical trials, observational studies or case reports evaluating gestrinone for lipedema, particularly as subcutaneous implants. This is an absence of evidence rather than evidence of ineffectiveness — its effectiveness and safety are simply unknown. Because no evidence supports it, off-label use (notably via subcutaneous implants) is not justified, and the safety of that route is unstudied. The Brazilian Society of Endocrinology and Metabolism (SBEM) and the Brazilian Lipedema Association oppose its use.

⚙ AI consolidation: Claude Opus 4.8 · openrouter · 2026-05-31 — evidence-bounded; the AI does not opine

Knowledge stateEvidence gap
Knowledge freshness100% recent · current evidence base
Created2026-05-30
Last updated2026-05-31
Human reviewnot yet reviewed
0supporting
1contradicting
0refining / context

Knowledge freshness = share of the 1 indexed evidence sources from the last 5 years (newest 2025, oldest 2025) . Low freshness flags an ageing evidence base — not that the answer is wrong.

Evidence over time

19342025First literature mention: Clinical and Biologic Considerations of Obesity and Certain Allied Conditions · originLack of Scientific Evidence for the Use of Gestrinone in the Treatment of Lipedema: A Systematic Review — Amato et al. (2025) · contradicting

supporting   contradicting   refining / context Each dot is a study, placed by year and coloured by whether the linked claim supports or contradicts the answer. As the surveillance loop runs, claim revisions and new evidence will extend this timeline. The hollow ring marks the first time this topic appears in the literature.

How to cite this version

    
    

Choose a format (Vancouver default). Citing a version captures the evidence state on that date; this page shows the current version — see version history.

What changed in this version

Answer recompiled after human curation of the claim set.

Supporting claims

Contradictory claims

Major uncertainty

No primary studies (trials, cohorts, or even case reports) on gestrinone for lipedema exist, so both its efficacy and the safety of subcutaneous implant administration remain entirely uncharacterized.

Version history

Key references

DOI:10.7759/cureus.97213